ETOP IBCSG Partners Foundation

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, ETOP IBCSG Partners Foundation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 5 completed later-stage tilt upper quartile by trial count

ETOP IBCSG Partners Foundation: 6 sponsored US clinical trials, none currently recruiting.

ETOP IBCSG Partners Foundation sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 5 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Early Breast Cancer, with 1 trials.

Upper-quartile sponsor footprint

ETOP IBCSG Partners Foundation sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

NCT02308085
COMPLETED Phase 3

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

NCT00659373
COMPLETED Phase 3

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410
COMPLETED Phase 3

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
COMPLETED Phase 3

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066703
COMPLETED Phase 3

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

NCT00074152

Phase Distribution

PhaseTrial count
Phase 3 5

Therapeutic Areas

Early Breast Cancer 1
Breast Cancer 1

How the ETOP IBCSG Partners Foundation archive is shaped

6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).

Phase mix: 5 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Early Breast Cancer (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

ETOP IBCSG Partners Foundation: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

ETOP IBCSG Partners Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share ETOP IBCSG Partners Foundation23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
ETOP IBCSG Partners Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ETOP IBCSG Partners Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ETOP IBCSG Partners Foundation page

6 registered trials is a research-attention snapshot, not an endorsement of ETOP IBCSG Partners Foundation or any single study.

  • None of ETOP IBCSG Partners Foundation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Early Breast Cancer is the condition ETOP IBCSG Partners Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Early Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

ETOP IBCSG Partners Foundation pipeline card: 6 registered trials from official public datasets.Report a data error.